Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that they will be
presenting at the J.P. Morgan 27th Healthcare Conference to be held on 12-15
January 2009 in San Francisco.

”It is very important for us to have been invited to present Exiqon at this
investor conference. It proves to us that our company is being recognized as a
key player in our industry and in the development of modern molecular
diagnostic tests for improved treatment selection”, says Lars Kongsbak,
president and CEO of Exiqon A/S.

The annual J.P. Morgan event is the most visited investor conference of its
kind.

Exiqon will be presenting its planned series of new molecular diagnostic tests
that are based on genetic profiling using miRNA biomarkers. In December 2008,
Exiqon announced the first in a series of new diagnostic tests to be launched
to help identify individual patients treatment needs based on genetic testing
(miRNA profiling) in line with the trend towards personalized medicine. The
first test to be launched is a prognostic test which will help identify stage
II colon cancer patients who may be at significantly higher risk for recurrence
and for whom adjuvant chemotherapy may be warranted.

Exiqon's presentation is scheduled for 15 January at 9:00 a.m. (PST).
Interested parties are invited to see the powerpoint presentation on the
investor section of Exiqon's website at www.exiqon.com.

Additional information: Lars Kongsbak, CEO, phone +45 45 66 08 88 (cell: +45 40
90 21 01)
Hans Henrik Chrois Christensen, CFO, phone +45 45 66 08 88 (cell: +45 40 90 21
31)

See the full press release in the attached PDF.

press_release_uk_jpm_conference_final_090107.pdf